glp-1 atrial fibrillation Mechanisms of Receptor Agonists in HFpEF: Exploring Weight-Dependent and Independent Drivers of Therapeutic Benefit Glucagon-like peptide-1 and atrial fibrillation

Once subcutaneously injected, acylated peptide spontaneously forms a depo at the injection site, leading to a delayed absorption into systemic circulation [55]

GLP-1Rs exhibit broad tissue distribution, spanning the pancreas, gastrointestinal tract, cardiovascular system, and central nervous system, allowing GLP-1 RAs to impact multiple organ systems 2,3

research indicates rapid weight regain and metabolic rebound occur when treatment ends without gradual tapering

doi: 10.1136/gut.38.6.916 [DOI] [PMC free article] [PubMed] [Google Scholar] 23.Campbell JE, Drucker DJ

A further in vitro study on myogenic differentiation confirmed that liraglutide could promote myogenic differentiation, alleviate myotube atrophy, and inhibit the upregulation of atrophy-induced MAFbx and MuRF1 mRNA expression, ultimately contributing to the preservation of muscle mass (145)